Maximal glaucoma therapy.

Suppr

超能文献

作者信息

Fechtner R D, Singh K

机构信息

New Jersey Medical School, Newark 07103, USA.

出版信息

J Glaucoma. 2001 Oct;10(5 Suppl 1):S73-5. doi: 10.1097/00061198-200110001-00026.

DOI:10.1097/00061198-200110001-00026

PMID:11890285

Abstract

摘要

相似文献

Maximal glaucoma therapy.

J Glaucoma. 2001 Oct;10(5 Suppl 1):S73-5. doi: 10.1097/00061198-200110001-00026.

Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.

Adv Ther. 2016 Sep;33(9):1628-34. doi: 10.1007/s12325-016-0389-3. Epub 2016 Jul 20.

Treatment Outcomes and Prognostic Factors of Selective Laser Trabeculoplasty for Open-angle Glaucoma Receiving Maximal-tolerable Medical Therapy.

J Glaucoma. 2016 Oct;25(10):785-789. doi: 10.1097/IJG.0000000000000411.

Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy.

J Ocul Pharmacol Ther. 2012 Oct;28(5):536-41. doi: 10.1089/jop.2012.0021. Epub 2012 Jun 25.

One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.

Graefes Arch Clin Exp Ophthalmol. 2017 Oct;255(10):2009-2015. doi: 10.1007/s00417-017-3727-5. Epub 2017 Jul 15.

Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.

J Glaucoma. 2017 Feb;26(2):96-100. doi: 10.1097/IJG.0000000000000552.

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.

Am J Ophthalmol. 1995 Oct;120(4):423-32. doi: 10.1016/s0002-9394(14)72655-8.

Glaucoma case report: a nutritional response.

Optometry. 2003 Dec;74(12):775-81.

Medical treatment as the initial therapy for open-angle glaucoma.

Semin Ophthalmol. 1992 Jun;7(2):81-91. doi: 10.3109/08820539209065096.

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma.

Am J Ophthalmol. 1999 May;127(5):625-6.

引用本文的文献

Short-term safety and efficacy of ripasudil as "add-on therapy" in glaucoma patients on maximum tolerable glaucoma medication.

Saudi J Ophthalmol. 2024 Dec 26;38(4):343-347. doi: 10.4103/sjopt.sjopt_201_24. eCollection 2024 Oct-Dec.

Effectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study.

Curr Ther Res Clin Exp. 2022 Nov 24;98:100689. doi: 10.1016/j.curtheres.2022.100689. eCollection 2023.

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension.

Clin Ophthalmol. 2019 Dec 5;13:2411-2419. doi: 10.2147/OPTH.S228777. eCollection 2019.

Long-term results of glaucoma drainage device surgery.

BMC Ophthalmol. 2019 Jan 10;19(1):14. doi: 10.1186/s12886-019-1027-z.

Pars plana Baerveldt tube insertion with pars plana vitrectomy for refractory glaucoma.

Oman J Ophthalmol. 2012 Jan;5(1):19-27. doi: 10.4103/0974-620X.94762.

Medical management of glaucoma: principles and practice.

Indian J Ophthalmol. 2011 Jan;59 Suppl(Suppl1):S88-92. doi: 10.4103/0301-4738.73691.

The path to open-angle glaucoma gene discovery: endophenotypic status of intraocular pressure, cup-to-disc ratio, and central corneal thickness.

Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3509-14. doi: 10.1167/iovs.09-4786. Epub 2010 Mar 17.

Practical approach to medical management of glaucoma.

Indian J Ophthalmol. 2008 May-Jun;56(3):223-30. doi: 10.4103/0301-4738.40362.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验